Olr286 inhibitors represent a specific class of chemical compounds that interact with the Olr286 receptor, which belongs to the family of olfactory receptors. Olfactory receptors are G-protein-coupled receptors (GPCRs) primarily found in the nasal epithelium and are responsible for detecting and transducing odorant signals into the brain. The Olr286 receptor is one of the numerous olfactory receptors encoded in the genome, each with distinct ligand specificities that contribute to the diversity of odor detection. Inhibitors targeting Olr286 are designed to specifically block or modulate the receptor's ability to bind to its natural ligands, thereby altering the receptor's signaling cascade. The molecular mechanisms of these inhibitors often involve binding to the receptor's active site, preventing the interaction with odorant molecules or causing conformational changes that disrupt the normal function of the receptor.
These inhibitors are crucial tools in understanding the structural and functional dynamics of the Olr286 receptor and related GPCRs. By studying these interactions, researchers can gain insights into the specificity and selectivity of ligand-receptor binding, the structural conformations of the receptor in both active and inactive states, and the subsequent intracellular signaling pathways triggered by receptor activation or inhibition. Additionally, Olr286 inhibitors contribute to the broader field of chemical biology by serving as molecular probes to dissect the complex networks of olfactory signal transduction. These studies can also extend to the exploration of receptor-ligand co-evolution and the evolutionary pressures that shaped the diversification of olfactory receptors across species. Thus, the investigation of Olr286 inhibitors is integral to advancing our understanding of olfactory receptor biology, receptor-ligand interactions, and the general principles of GPCR function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Inhibits phosphodiesterases, leading to increased cAMP, possibly affecting Olr286 signaling. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Phosphodiesterase inhibitor, may enhance cAMP-mediated pathways linked to Olr286. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
ROCK inhibitor, possibly modulating GPCR pathways, indirectly affecting Olr286. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MAPK/ERK inhibitor, could alter pathways interacting with Olr286 signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor, might modulate pathways interconnected with Olr286 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor, potentially influencing pathways associated with Olr286. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor, could affect signaling cascades linked to Olr286. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Selectively inhibits MEK, possibly impacting Olr286-related signaling. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
Calcium chelator, might indirectly influence Olr286 activity via calcium signaling. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
SERCA pump inhibitor, potentially modulating calcium stores affecting Olr286. | ||||||